Eczema, also known as atopic dermatitis or AD, is a chronic and unpredictable disease characterized by an intense and persistent itch.
85% of children show their first symptom of eczema before the age of 5 years old.
Eczema ranks 1st in global burden of disease for all skin diseases.
Eczema has been shown to impact sleep.
Eczema predominantly affects children, and the prevalence is only increasing. About 13% of children in the US have eczema, and it most commonly appears as dry, itchy patches on the face or neck, and in the folds of the elbows or knees.
Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please read the Prescribing and Patient Information for VTAMA cream and discuss it with your doctor.
Back to top
